Transient monosomy 7 in a chronic myelogenous leukemia patient during nilotinib therapy: a case report

Majd D. Jawad, Ronald S. Go, Rhett P. Ketterling, Kebede H. Begna, Kaaren K. Reichard & Min Shi

1Division of Hematology, Mayo Clinic, Rochester, Minnesota
2Division of Laboratory Genetics, Mayo Clinic, Rochester, Minnesota
3Division of Hematopathology, Mayo Clinic, Rochester, Minnesota

Correspondence
Min Shi, Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Tel: 507 284 2396; Fax: 507 284 5115; E-mail: Shi.Min@mayo.edu

Funding Information
No sources of funding were declared for this study.

Received: 1 October 2015; Revised: 9 December 2015; Accepted: 16 January 2016

Clinical Case Reports 2016; 4(3): 282–286
doi: 10.1002/ccr3.506

Key Clinical Message
Tyrosine kinase inhibitor treated chronic myelogenous leukemia patients with monosomy 7 arising in Philadelphia chromosome negative (Ph−) cells tend to evolve into MDS/AML. However, monosomy 7 in Ph− cells can be a transient finding, and it is not an absolute indication of the emergence of a new myeloid malignancy.

Keywords
chronic myelogenous leukemia, monosomy 7.

Introduction
Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm that is always associated with a BCR-ABL1 fusion gene. Most often, the BCR-ABL1 fusion is the result of a reciprocal translocation involving chromosomes 9 and 22 with the derivative chromosome 22 harboring the active abnormal fusion. The derivative chromosome 22 is also known as the Philadelphia chromosome. The BCR-ABL1 fusion gene results in an unregulated tyrosine kinase activity, responsible for the expansion of myeloid elements in CML [1]. Tyrosine kinase inhibitors (TKIs) block the initiation of the BCR-ABL1 pathway, and are currently used as a first-line treatment for CML patients. However, it has been reported that after treatment with TKIs, Philadelphia chromosome negative (Ph-negative) clones can emerge with various cytogenetic abnormalities associated with different outcomes [2–22]. Most abnormalities are similar to those associated with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), including trisomy 8, monosomy 7 and 20q−. Based on published data, CML patients that develop chromosome 7 abnormalities in Ph− cells, particularly monosomy 7, appear to have the greatest risk of developing MDS/AML [6, 12, 13]. We report a case of a CML patient who achieved complete hematologic, cytogenetic, and molecular remission on nilotinib as a first-line treatment, but was found to develop monosomy 7 in Ph− cells. The monosomy 7 clone was transient and disappeared after one year follow-up while maintaining nilotinib and without the initiation of additional therapy. The patient has not shown any morphologic or clinical progression to MDS/AML.

Case Report
The patient is a 54-year-old Caucasian male with no significant past medical history who presented with splenomegaly. The complete blood cell count (CBC) showed a hemoglobin (Hb) of 7.2 g/dL (reference range, 13.5–17.5 g/dL), white blood cells (WBCs) of 244.1 × 10^9/L (reference range), 3.5–10.5 × 10^9/L, and platelets (PLTs) of 1706 × 10^9/L (reference range, 150–450 × 10^9/L). A bone marrow (BM) biopsy, in conjunction with
Cytogenetics, was diagnostic of CML, accelerated phase (10% myeloblasts). The conventional karyotype showed t(9;22;19)(q34;q11.2;q13.1) in 20 metaphases and no other cytogenetic abnormalities (Fig. 1). Fluorescence in situ hybridization (FISH) revealed BCR/ABL1 fusion in 94.2% of nuclei. The morphological, cytogenetic, and molecular characteristics are summarized in Table 1. The patient was started on nilotinib 400 mg P.O. twice a day. Three months after treatment, the patient developed pancytopenia (Hb of 12.4 g/dL, WBC of 2.2 × 10^9/L, PLTs of 112 × 10^9/L); thus, the nilotinib dose was decreased to 600 mg P.O. daily. The patient tolerated the treatment with no significant symptoms. After 6 months, he achieved complete hematologic, major cytogenetic, and major molecular remission (Table 1). Repeat BM biopsy 13 months after diagnosis showed no evidence of residual CML or overt dysplasia except the presence of occasional small megakaryocytes. Interest-

Figure 1. Bone marrow chromosome karyotypes. (A) CML diagnosis: The diagnostic cytogenetic analysis shows a three-way translocation involving chromosomes 9, 22, and 19 (highlighted by the arrow heads). (B) CML in hematologic and cytogenetic remission on Nilotinib therapy: cytogenetic analysis shows monosomy 7 and absence of the complex 9;22;19 translocation (Ph-negative metaphase).
ingly, while there was no evidence of the complex 9;22;19 translocation, the karyotype showed monosomy 7 in 15 of 20 metaphases, indicating the emergence of an unrelated myeloid clone. A FISH panel for MDS was performed, using probes that recognize inv(3), -5/5q-, -7/7q-, +8, 13q-, 20q-, 11q23/MLL, and 17p-. This study confirmed the presence of monosomy 7 in 61.5% of nuclei, and did not detect any other abnormalities. He was continued on nilotinib 600 mg P.O. daily with close follow-up. Eighteen months after the initial diagnosis, the patient underwent another BM biopsy which showed no significant morphologic changes, with monosomy 7 detected in six of 20 metaphases. Repeat BM biopsy 30 months after the initial diagnosis showed a morphologically normal bone marrow with BCR/ABL1 fusion in 0.007% of total abl by RT-PCR, and a normal karyotype in 20 metaphases with complete disappearance of the monosomy 7 clone. Repeat MDS FISH study on his peripheral blood was completely normal. The patient is currently in complete remission at 40 months following diagnosis.

**Discussion**

Of CML patients treated with TKIs, approximately 2–10% of patients develop cytogenetic abnormalities in Ph-negative cells [12, 15, 21]. Although most remain stable, a subset of patients, especially those with monosomy 7 abnormality, are at risk of developing MDS or AML [6, 12, 13]. For those who displayed monosomy 7 without developing MDS or AML, persistent monosomy 7 has been observed [2, 4, 9]. It is uncertain whether MDS changes would become apparent in patients with persistent monosomy 7 after long-term follow-up.

The majority of reports on cytogenetic abnormalities developing in Ph-negative cells are observed in CML patients treated with Imatinib, the first generation of TKI. Very few cytogenetic abnormalities in Ph-negative cells have been reported in CML patients treated with Nilotinib [23], a new aminopyrimidine-derivative tyrosine kinase inhibitor that has been shown to be a more potent inhibitor than Imatinib and can be considered as a first-line therapy for CML [24]. Zeidan et al. [22] reported a case of monosomy 7 in a CML patient treated with imatinib followed by nilotinib, and Larsson et al. [13] reported a CML patient on dasatinib (similar to Nilotinib) therapy developing a monosomy 7 clone. Unlike our patient, MDS and AML, respectively, developed in both of these patients. To the best of our knowledge, this is the first report of transient monosomy 7 in Ph-negative cells with nilotinib as the first-line treatment.

The mechanisms for the emergence of such clones remain unclear. Bumm et al. [5] suggests that CML patients have been exposed to genomic damage, which produces multiple abnormal clones, including the t (9;22) clone. These clones may not be apparent during the proliferative phase of the Ph-positive clone. Therefore, TKI treatment suppresses Ph-positive clone proliferation and allows the Ph-negative clones to emerge. The second suggested mechanism by O’Dwyer et al. [18] is that these clonal abnormalities are a direct consequence of TKI toxicity. The third possible mechanism is indirect toxicity of TKI by inhibiting the normal role of ABL tyrosine kinase in p53-mediated growth arrest after DNA damage [4]. However, clonal abnormalities in Ph− cells have been reported in CML patients after interferon treatment suggesting the genesis of these cytogenetic clones is not solely associated with the initiation of TKI therapy [25]. Thus, the exact etiology behind the appearance of these abnormal clones is not fully understood.

In summary, this case illustrates that monosomy 7 occurring in Ph− cells can be a transient finding in CML patients on TKI treatment, and that it is not an absolute indication of the emergence of a new myeloid malignancy. In addition, while most cytogenetic abnormal, Ph− myeloid clone have thus far been identified in CML patients treated with imatinib, with the increasing use of newer TKI such as Nilotinib, these Ph− clones may be more commonly associated with the second generation of TKI.

**Table 1. Summary of the morphological, cytogenetic, and molecular data of the patient.**

| Date       | Conventional karyotype | FISH BCR/ABL1 | PCR BCR/ABL1 | Morphology               |
|------------|------------------------|---------------|--------------|--------------------------|
| Diagnosis  | 46,XY,t(9;22;19)[q34;q11.2;q13.1][20] | 94.2%         | 64%          | CML                      |
| +6 months  | 46,XY,t(9;22;19)[q34;q11.2;q13.1][4]/ | N/A           | 5.2%         | Normal                   |
| +13 months | 45,XY,-7[15]/46,XY[5]    | Normal        | 0.4%         | Occasional small megakaryocytes |
| +18 months | 45,XY,-7[6]/46,XY[14]    | N/A           | 0.08%        | Occasional small megakaryocytes |
| +30 months | 46,XY[20]               | N/A           | 0.007%       | Normal                   |
References

1. Sawyers, C. L. 1999. Chronic myeloid leukemia. N. Engl. J. Med. 340:1330–1340.

2. Abruzzese, E., A. Gozzetti, S. Galimberti, M. M. Trawinska, T. Caravita, A. Siniscalchi, et al. 2007. Characterization of Ph-negative abnormal clones emerging during imatinib therapy. Cancer 109:2466–2472.

3. Bacher, U., A. Hochhaus, U. Berger, W. Hiddemann, R. Hehlmann, T. Haferlach, et al. 2005. Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha. Leukemia 19:460–463.

4. Besalduch, J., A. Gutierrez, R. Parody, and S. T. Bernu. 2003. Chromosomal abnormalities in Philadelphia (Ph)-negative cells of patients with chronic myeloid leukemia treated with Imatinib (ST1571). Haematologica 88:ELT03.

5. Bumm, T., C. Muller, H. K. Al-Ali, K. Krohn, P. Shepherd, E. Schmidt, et al. 2003. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 101:1941–1949.

6. Deininger, M. W., J. Cortes, R. Paquette, B. Park, A. Hochhaus, M. Baccarani, et al. 2007. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer 110:1509–1519.

7. Espinet, B., A. C. Oliveira, C. Boque, A. Domingo, E. Alonso, and F. Sole. 2005. Clonal cytogenetic abnormalities in patients with chronic myeloid leukemia in complete cytogenetic response to imatinib mesylate. Haematologica 90:556–558.

8. Groves, M. J., M. Sales, L. Baker, M. Griffiths, N. Pratt, and S. Tauro. 2011. Factors influencing a second myeloid malignancy in patients with Philadelphia-negative-7 or del (7q) clones during tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer Genet. 204:39–44.

9. Guilbert-Douet, N., F. Morel, M. J. Le Bris, C. Berthou, P. Morice, P. Bourquard, et al. 2004. Clonal chromosomal abnormalities in the Philadelphia chromosome negative cells of chronic myeloid leukemia patients treated with imatinib. Leukemia 18:1140–1142.

10. Hackanson, B., A. Ruckert, and M. Lubbert. 2009. Hyperleukocytotic secondary acute myeloid leukemia (AML) with sole monosomy 7 as sequela of Philadelphia chromosome positive chronic myeloid leukemia (CML). Eur. J. Haematol. 83:611–612.

11. Jabour, E., H. M. Kantarjian, L. V. Abruzzo, S. O’Brien, G. Garcia-Manero, S. Verstovsek, et al. 2007. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 110:2991–2995.

12. Kovitz, C., H. Kantarjian, G. Garcia-Manero, L. V. Abruzzo, and J. Cortes. 2006. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 108:2811–2813.

13. Larsson, N., R. Billstrom, H. Lilljebjorn, C. Lassen, J. Richter, M. Eklom, et al. 2010. Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells. Cancer Genet. Cytogenet. 199:89–95.

14. Lin, Y. L., H. Bruyere, D. E. Horsman, T. Pantzar, M. J. Barnett, D. E. Hogge, et al. 2006. Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors. Cancer Genet. Cytogenet. 170:16–23.

15. Medina, J., H. Kantarjian, M. Talpaz, S. O’Brien, G. Garcia-Manero, F. Giles, et al. 2003. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 98:1905–1911.

16. Meeus, P., H. Demuyynck, P. Martiat, L. Michaux, E. Wouters, and A. Hagemeijer. 2003. Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with imatinib. Leukemia 17:465–467.

17. Navarro, J. T., E. Feliu, J. Grau, B. Espinet, D. Colomer, J. M. Ribera, et al. 2007. Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome. Am. J. Hematol. 82:849–851.

18. O’Dwyer, M. E., M. J. Mauro, G. Kurilik, M. Mori, S. Balleisen, S. Olson, et al. 2002. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood 100:1628–1633.

19. O’Shea, D., G. Crotty, P. Carroll, E. Conneally, S. O’Dwyer, M. E., M. J. Mauro, G. Kurilik, M. Mori, S. Balleisen, S. Olson, et al. 2002. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood 100:1628–1633.

20. Perel, J. M., C. McCarthy, O. Walker, I. Irving, B. Williams, and G. A. Kennedy. 2005. Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate. Haematologica 90(Suppl): ECR25.

21. Terre, C., V. Eclache, P. Rousselot, M. Imbert, C. Charrin, C. Gervais, et al. 2004. Report of 34 patients with clonal
chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 18:1340–1346.

22. Zeidan, A., S. Kakati, B. Anderson, M. Barcos, and M. Wetzler. 2007. Monosomy 7 in t(9;22)-negative cells during nilotinib therapy in an imatinib-resistant chronic myeloid leukemia case. Cancer Genet. Cytogenet. 176:169–171.

23. Wang, H., J. Jin, Y. Wang, X. Huang, and J. Huang. 2013. Clonal chromosomal abnormalities in Philadelphia-negative cells in chronic myeloid leukemia patients treated with nilotinib used in first-line therapy. Ann. Hematol. 92:1625–1632.

24. Saglio, G., D. W. Kim, S. Issaragrisil, P. le Coutre, G. Etienne, C. Lobo, et al. 2010. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 362:2251–2259.

25. Fayad, L., H. Kantarjian, S. O'Brien, D. Seong, M. Albitar, M. Keating, et al. 1997. Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases. Leukemia 11:767–771.